EE391 Budget Impact of Andexanet ALFA for Gastrointestinal Bleeding Associated with Factor Xa Inhibitors from a US Hospital Perspective

S Deitelzweig,Bd Cash,Jn Goldstein,Rs Blissett,B Lovelace,Mj Christoph,G Fermann

doi:10.1016/j.jval.2022.04.639

EE391 Budget Impact of Andexanet ALFA for Gastrointestinal Bleeding Associated with Factor Xa Inhibitors from a US Hospital Perspective

S Deitelzweig, Bd Cash + Show 5 more

Open Access

https://doi.org/10.1016/j.jval.2022.04.639

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 25, 2022
License type: publisher-specific-oa

Affiliation: University of Queensland, The University of Texas Health Science Center at Houston, Massachusetts General Hospital, AstraZeneca (United States), Alexion Pharmaceuticals (United States), University of Cincinnati

#Factor Xa Inhibitors #US Acute Care Hospital + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Oral Factor Xa (FXa) inhibitors are used to treat and prevent thrombotic events but may exacerbate acute major bleeding. This analysis calculated the budget impact of using Andexanet alfa (andexanet), a novel specific reversal agent for FXa inhibitors, to treat FXa inhibitor-related major gastrointestinal bleeding from a US acute care hospital perspective.

Full Text